Current:Home > Contact-usWorld's first gene therapy for sickle cell and thalassemia approved in the U.K.-LoTradeCoin
World's first gene therapy for sickle cell and thalassemia approved in the U.K.
View Date:2024-12-23 23:44:49
Britain's medicines regulator has authorized the world's first gene therapy treatment for sickle cell disease, in a move that could offer relief to thousands of people with the crippling disease in the U.K.
In a statement on Thursday, the Medicines and Healthcare Regulatory Agency said it approved Casgevy, the first medicine licensed using the gene editing tool CRISPR, which won its makers a Nobel Prize in 2020.
Casgevy — made by the Boston-based Vertex Pharmaceuticals (Europe) Ltd. and CRISPR Therapeutics — was approved by the agency for the treatment for patients with sickle cell disease and thalassemia who are 12 years old and over.
To date, bone marrow transplants, extremely arduous procedures that come with very unpleasant side effects, have been the only long-lasting treatment.
"The future of life-changing cures resides in CRISPR based (gene-editing) technology," said Dr. Helen O'Neill of University College London.
"The use of the word 'cure' in relation to sickle cell disease or thalassemia has, up until now, been incompatible," she said in a statement, calling the MHRA's approval of gene therapy "a positive moment in history."
Both sickle cell disease and thalassemia are caused by mistakes in the genes that carry hemoglobin, the protein in red blood cells that carry oxygen.
In people with sickle cell — which is particularly common in people with African or Caribbean heritage — a genetic mutation causes the cells to become crescent-shaped, which can block blood flow and cause excruciating pain, organ damage, stroke and other problems.
In people with thalassemia, the genetic mutation can cause severe anemia. Patients typically require blood transfusions every few weeks, and injections and medicines for their entire life. Thalassemia predominantly affects people of South Asian, Southeast Asian and Middle Eastern heritage.
The new medicine, Casgevy, works by targeting the problematic gene in a patient's bone marrow stem cells so that the body can make properly functioning hemoglobin.
Patients first receive a course of chemotherapy, before doctors take stem cells from the patient's bone marrow and use genetic editing techniques in a laboratory to fix the gene. The cells are then infused back into the patient for a permanent treatment. Patients must be hospitalized at least twice — once for the collection of the stem cells and then to receive the altered cells.
Britain's regulator said its decision to authorize the gene therapy for sickle cell disease was based on a study done on 29 patients, of whom 28 reported having no severe pain problems for at least one year after being treated. In the study for thalassemia, 39 out of 42 patients who got the therapy did not need a red blood cell transfusion for at least a year afterward.
Gene therapy treatments can cost millions of dollars and experts have previously raised concerns that they could remain out of reach for the people who would benefit most.
Last year, Britain approved a gene therapy for a fatal genetic disorder that had a list price of £2.8 million ($3.5 million). England's National Health Service negotiated a significant confidential discount to make it available to eligible patients.
Vertex Pharmaceuticals said it had not yet established a price for the treatment in Britain and was working with health authorities "to secure reimbursement and access for eligible patients as quickly as possible."
In the U.S., Vertex has not released a potential price for the therapy, but a report by the nonprofit Institute for Clinical and Economic Review said prices up to around $2 million would be cost-effective. By comparison, research earlier this year showed medical expenses for current sickle cell treatments, from birth to age 65, add up to about $1.6 million for women and $1.7 million for men.
Medicines and treatments in Britain must be recommended by a government watchdog before they are made freely available to patients in the national health care system.
Casgevy is currently being reviewed by the U.S. Food and Drug Administration; the agency is expected to make a decision early next month, before considering another sickle cell gene therapy.
Millions of people around the world, including about 100,000 in the U.S., have sickle cell disease. It occurs more often among people from places where malaria is or was common, like Africa and India, and is also more common in certain ethnic groups, such as people of African, Middle Eastern and Indian descent. Scientists believe being a carrier of the sickle cell trait helps protect against severe malaria.
Dr. Jon LaPook has reported on another effort to harness gene therapy to cure sickle cell disease. Watch that story in the video below:
- In:
- Sickle Cell Disease
- Chemotherapy
- Britain
- United Kingdom
- Thalassemia
- CRISPR
veryGood! (423)
Related
- Bankruptcy judge questioned Shilo Sanders' no-show at previous trial
- Horoscopes Today, December 25, 2023
- Free People's After-Holiday Sale Is Too Good To Be True With Deals Starting at Just $24
- 2023 in Climate News
- How Ben Affleck Really Feels About His and Jennifer Lopez’s Movie Gigli Today
- What is Boxing Day? Learn more about the centuries-old tradition
- North Dakota Republican leaders call on state rep to resign after slurs to police during DUI stop
- Russian presidential hopeful loses appeal against authorities’ refusal to register her for the race
- What Just Happened to the Idea of Progress?
- Map shows where blue land crabs are moving, beyond native habitat in Florida, Texas
Ranking
- Will Aaron Rodgers retire? Jets QB tells reporters he plans to play in 2025
- Teenager Najiah Knight wants to be the first woman at bull riding’s top level. It’s an uphill dream
- Almcoin Trading Center: Token Crowdfunding Model
- Disney says in lawsuit that DeSantis-appointed government is failing to release public records
- Cowboys owner Jerry Jones responds to CeeDee Lamb's excuse about curtains at AT&T Stadium
- Anthropologie's End-of Season Sale is Here: Save an Extra 40% off on Must-Have Fashion, Home & More
- Next year will be the best year to buy a new car since 2019, economist says
- Pregnant 18-year-old who never showed for doctor's appointment now considered missing
Recommendation
-
Shawn Mendes quest for self-discovery is a quiet triumph: Best songs on 'Shawn' album
-
Indiana mom Rebekah Hubley fights to keep her adopted, disabled son Jonas from being deported
-
Search resumes for woman who went into frozen Alaska river to save her dog
-
Actor Lee Sun-kyun of Oscar-winning film ‘Parasite’ dies
-
Target will be closed on Thanksgiving: Here’s when stores open on Black Friday
-
Almcoin Trading Exchange: The Debate Over Whether Cryptocurrency is a Commodity or a Security?
-
Almcoin Trading Center Analysis of the Development Process of Bitcoin
-
Actor Lee Sun-kyun of Oscar-winning film 'Parasite' is found dead in Seoul